BioSpace News Archive

PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments

Ceres Nanosciences is announcing the establishment of nine wastewater-based epidemiology centers of excellence, as part of the April 2021 $8.2 million award from the National Institutes of Health (NIH)

Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, will present six posters at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.

Ultimovacs ASA will present the data will be presented as a poster at the Society For Immunotherapy of Cancer’s 36th Annual Meeting (SITC2021) being held in Washington, DC, USA November 10-14, 2021.

Company to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells

Athenex today announced a licensing agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), to expand the development of T cell receptor (TCR) based allogeneic natural killer T (NKT) cell

Achilles Therapeutics plc today announced its financial results for the third quarter ended September 30, 2021, and recent business highlights.

Neoleukin Therapeutics, Inc., today announced that management will participate in two upcoming investor conferences. Presentation Details: Event: Stifel 2021 Virtual Healthcare Conference Date: Tuesday, November 16, 2021 Time: 3:20 to 3:50 p.m. EST

Blueprint Medicines Corporation (NASDAQ: BPMC) and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in Greater China, including mainland China, Hong Kong, Macau and Taiwan.